COMMUNIQUÉS West-GlobeNewswire

BioSenic patent granted in Canada for broader protection of ATO therapeutic platform
30/01/2024
PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through [...]
Le brevet de BioSenic est accordé au Canada pour une protection plus large de sa plate-forme thérapeutique ATO
30/01/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Le brevet de BioSenic est accordé au Canada pour une protection plus large de sa plate-forme thérapeutique ATO Le brevet sur la composition de la matière couvre l' [...]
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
30/01/2024
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE ® is the first oral targeted therapy approved in Hong Kong for [...]
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
30/01/2024
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious [...]
Among the ongoing attacks on Ukraine, religious leaders aim to unite the Ukrainian religious diaspora and foster collaboration between Ukraine and the U.S. through Ukrainian Week 2024
30/01/2024
Ukrainian soldiers, returned children from Russia and Ukrainian delegates and parliament members set to attend Ukrainian Week 2024 WASHINGTON, D.C. and KYIV, Ukraine, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, prominent [...]
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
29/01/2024
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B [...]
Castellum Announces Closing of $2.7 Million Registered Direct Offering
29/01/2024
BETHESDA, Md., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government today announced [...]
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
29/01/2024
The UK MHRA approval follows approvals by the U.S. FDA and the European Commission Cidara is entitled to receive a milestone payment of approximately $2.8 million from Mundipharma SAN DIEGO, Jan. 29, 2024 (GLOBE [...]
Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th
29/01/2024
CHARLOTTE, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast [...]
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29/01/2024
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
Nanobiotix annonce l’atteinte des conditions pour un paiement d'étape de développement de 20 M$ lié à l'étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
29/01/2024
PARIS et CAMBRIDGE, Mass., 29 janv. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Immunocore Announces Proposed Convertible Senior Notes Offering
29/01/2024
Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today announced its [...]
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
29/01/2024
WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/01/2024
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
29/01/2024
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
29/01/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“ [...]
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
29/01/2024
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29/01/2024
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
Range Impact Announces Former Ohio Congressman Zack Space and Former Ohio Senator Jay Hottinger Have Joined the Company as Strategic Advisors
29/01/2024
CLEVELAND, OHIO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative [...]

Pages